Significant function and research progress of biomarkers in gastric cancer (Review)
- Authors:
- Dong Mei Ye
- Gaosheng Xu
- Wei Ma
- Yuxuan Li
- Weiru Luo
- Yiyang Xiao
- Yong Liu
- Zhiwei Zhang
-
Affiliations: Key Laboratory of Cancer Cellular and Molecular Pathology, Cancer Research Institute of Hengyang Medical College, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Surgery, Yueyang Maternal and Child Health Hospital, Yueyang, Hunan 414000, P.R. China, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Pathology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, Jiangxi 330006, P.R. China - Published online on: November 11, 2019 https://doi.org/10.3892/ol.2019.11078
- Pages: 17-29
-
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, Tsujitani S, Ono H, Tanabe S, Fukagawa T, et al: Five-year survival analysis of surgically resected gastric cancer cases in Japan: A retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 21:144–154. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sumiyama K: Erratum to: Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric Cancer. 20:5622017. View Article : Google Scholar : PubMed/NCBI | |
|
Ren W, Yu J, Zhang ZM, Song YK, Li YH and Wang L: Missed diagnosis of early gastric cancer or high-grade intraepithelial neoplasia. World J Gastroenterol. 19:2092–2096. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nie Y, Wu K, Yu J, Liang Q, Cai X, Shang Y, Zhou J, Pan K, Sun L, Fang J, et al: A global burden of gastric cancer: The major impact of China. Expert Rev Gastroenterol Hepatol. 11:651–661. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fock KM: Review article: The epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li ZS and Li Q: The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 40:351–354. 2011.(In Chinese). PubMed/NCBI | |
|
Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 61:1–241. 1994.PubMed/NCBI | |
|
van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, et al: Hereditary diffuse gastric cancer: Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 52:361–374. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Saigusa S, Tanaka K, Mohri Y, Ohi M, Shimura T, Kitajima T, Kondo S, Okugawa Y, Toiyama Y, Inoue Y and Kusunoki M: Clinical significance of RacGAP1 expression at the invasive front of gastric cancer. Gastric Cancer. 18:84–92. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol. 71:127–164. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI | |
|
Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, Chen DT, Marquez DD and Hodul PJ: Does histology really influence gastric cancer prognosis? J Gastrointest Oncol. 8:1026–1036. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
NIH-FDA conference: Biomarkers and surrogate endpoints: Advancing clinical research and applications. Abstracts. Dis Markers. 14:187–334. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Becking GC and Chen BH: International programme on chemical safety (IPCS) environmental health criteria on boron human health risk assessment. Biol Trace Elem Res. 66:439–452. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M and Dingding C: The relevance of gastric cancer biomarkers in prognosis and pre- and post-chemotherapy in clinical practice. Biomed Pharmacother. 95:1082–1090. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Strimbu K and Tavel JA: What are biomarkers? Curr Opin HIV AIDS. 5:463–466. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Meng FP, Ding J, Yu ZC, Han QL, Guo CC, Liu N and Fan DM: Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J Gastroenterol. 11:1833–1836. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ohtsu A, Yoshida S and Saijo N: Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 24:2188–2196. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tatsuta M, Itoh T, Okuda S, Yamamura H, Baba M and Tamura H: Carcinoembryonic antigen in gastric juice as an aid in diagnosis of early gastric cancer. Cancer. 46:2686–2692. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S and Aikou T: Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol. 32:41–44. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yin LK, Sun XQ and Mou DZ: Value of combined detection of serum CEA, CA72-4, CA19-9 and TSGF in the diagnosis of gastric cancer. Asian Pac J Cancer Prev. 16:3867–3870. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ren J, Chen Z, Juan SJ, Yong XY, Pan BR and Fan DM: Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer. 88:280–285. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T and Takahashi K: Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 22:133–141. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Miki K: Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 9:245–253. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano K and Graham DY: Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 15:1833–1843. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Graham DY: Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 148:719–731.e3. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Konturek SJ, Starzynska T, Konturek PC, Karczewska E, Marlicz K, Lawniczak M, Jaroszewicz-Heigelman H, Bielanski W, Hartwich A, Ziemniak A and Hahn EG: Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. Scand J Gastroenterol. 37:891–898. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M and Graham DY: Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer. 115:463–469. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X and Yuan Y: A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol. 112:704–715. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shiroshita H, Watanabe H, Ajioka Y, Watanabe G, Nishikura K and Kitano S: Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. Pathol Int. 54:311–321. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, et al: Determinants of Epstein-Barr virus-positive gastric cancer: An international pooled analysis. Br J Cancer. 105:38–43. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Zhang GJ, Wang J, Zheng KY and Fu W: Current status of lymph node micrometastasis in gastric cancer. Oncotarget. 8:51963–51969. 2017.PubMed/NCBI | |
|
Hata M, Machi J, Mamou J, Yanagihara ET, Saegusa-Beecroft E, Kobayashi GK, Wong CC, Fung C, Feleppa EJ and Sakamoto K: Entire-volume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers. Pathol Oncol Res. 17:835–841. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Giorgadze TA, Baloch ZW, Pasha T, Zhang PJ and Livolsi VA: Lymphatic and blood vessel density in the follicular patterned lesions of thyroid. Mod Pathol. 18:1424–1431. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 19:739–744. 1965. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Aziz A, Ahmed RA and Ibrahiem AT: Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages. Ann Diagn Pathol. 30:1–7. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Genc CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, Klumpen HJ, van Eijck C and Nieveen VDE: Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol. 25:2467–2474. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Wu N and Li J: Novel targeted agents for gastric cancer. J Hematol Oncol. 5:312012. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al: Amplification of HER-2 in gastric carcinoma: Association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gravalos C and Jimeno A: HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, et al: Lung cancer screening, version 1.2015: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 13:23–34. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2 testing in gastric cancer: A practical approach. Mod Pathol. 25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 29:3968–3976. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. Bmc Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI | |
|
Derde LPG, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJL, Gniadkowski M, Hryniewicz W, Empel J, Dautzenberg M, Annane D, et al: Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: An interrupted time series study and cluster randomised trial. Lancet Infect Dis. 14:31–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J and Ou SH: Towards the goal of personalized medicine in gastric cancer-time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. Discov Med. 16:7–14. 2013.PubMed/NCBI | |
|
Javle M, Li Y, Tan D, Dong X, Chang P, Kar S and Li D: Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One. 9:e859422014. View Article : Google Scholar : PubMed/NCBI | |
|
Elice F, Rodeghiero F, Falanga A and Rickles FR: Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 22:115–128. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L: Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 29 (Suppl 1):i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ and Finn RS: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et al: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Guo W, Zhang W, Yin J, Zhang J, Zhu X, Liu T, Chen Z, Wang B, Chang J, et al: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. BMC Cancer. 17:1882017. View Article : Google Scholar : PubMed/NCBI | |
|
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, et al: Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. Br J Cancer. 114:505–509. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology. 52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Catenacci D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B and Bondarenko I: Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1467–1482. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS and Bae JM: MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 26:1632–1641. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS and Kim ST: c-MET overexpression in colorectal cancer: A poor prognostic factor for survival. Clin Colorectal Cancer. 17:165–169. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pasquini G and Giaccone G: C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs. 27:363–375. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T and Hatake K: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 33:3905–3910. 2013.PubMed/NCBI | |
|
Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A and Salgia R: Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 1:573–579. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Batran SE, Ducreux M and Ohtsu A: mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 130:491–496. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, et al: Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 31:3935–3943. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, et al: Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: Possible role for predictive biomarkers. Cancer Chemother Pharmacol. 76:61–67. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, et al: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17:1697–1708. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singh P, Toom S and Huang Y: Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 10:1052017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Wang M, Yang X, Wang Y, Yu L, Sun J and Ding J: Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery. Theranostics. 9:6080–6098. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 141:476–485, 485.e1-e11. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al: Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 145:554–565. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Drake CG and Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF and Wang D: Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 9:901–909. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4:127ra372012. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y, Chen Y, Shi Q, Yu G and Zhang X: PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, et al: Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res. 21:4286–4293. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Giuliani J and Bonetti A: Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: Cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncol. 97:143–145. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kerr KM and Hirsch FR: Programmed death ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med. 140:326–331. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: Multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 4:902016. View Article : Google Scholar : PubMed/NCBI | |
|
Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al: Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hou J, Yu Z, Xiang R, Li C and Wang L, Chen S, Li Q, Chen M and Wang L: Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 96:284–291. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 20:273–281. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 4:e1800132018. View Article : Google Scholar : PubMed/NCBI | |
|
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, et al: Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 86:37–45. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE and Pazdur R: FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 24:103–109. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Joshi SS, Maron SB and Catenacci DV: Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 14:417–430. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, et al: Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. Jul 26–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, et al: Abundant PD-L1 expression in epstein-barr virus-infected gastric cancers. Oncotarget. 7:32925–32932. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F and Sun W: Programmed death-ligand 1 expression is common in gastric cancer associated with epstein-barr virus or microsatellite instability. Am J Surg Pathol. 40:1496–1506. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu H and Zhou Z: Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5. Zhonghua Wei Chang Wai Ke Za Zhi. 21:160–164. 2018.(In Chinese). PubMed/NCBI | |
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, et al: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 33:853–861.e4. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Das PM and Singal R: DNA methylation and cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S and Miyazaki K: Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients. J Gastroenterol. 42:866–873. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK and Sung JJ: Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 92:2190–2194. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ikoma H, Ichikawa D, Daito I, Nobuyuki T, Koike H, Okamoto K, Ochiai T, Ueda Y, Yamagishi H and Otsuji E: Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology. 54:946–950. 2007.PubMed/NCBI | |
|
Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E and Chiba T: Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 29:2619–2625. 2009.PubMed/NCBI | |
|
Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S and Motoyama T: Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 97:51–56. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC, Chiu CC, Chen LT, Chang JY, Hsiao SH and Leu YW: Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 15:982015. View Article : Google Scholar : PubMed/NCBI | |
|
Choi SJ, Jung SW, Huh S, Chung YS, Cho H and Kang H: Alteration of DNA methylation in gastric cancer with chemotherapy. J Microbiol Biotechnol. 27:1367–1378. 2017.PubMed/NCBI | |
|
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al: Landscape of transcription in human cells. Nature. 489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Guttman M and Rinn JL: Modular regulatory principles of large non-coding RNAs. Nature. 482:339–346. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kwok ZH and Tay Y: Long noncoding RNAs: Lincs between human health and disease. Biochem Soc Trans. 45:805–812. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP and Chen CZ: Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al: Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis. Lancet Oncol. 13:633–641. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N: Molecular pathology of gastric cancer: Research and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: A new player enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B and Song ZS: MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int. 13:682013. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Cui L, Ye G, Zheng T, Song H, Xia T, Yu X, Xiao B, Le Y and Guo J: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 33:2349–2355. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bhan A and Mandal SS: Long noncoding RNAs: Emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 9:1932–1956. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Yin C, Dang Y, Ye F and Zhang G: Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 5:115162015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J and Fang G: Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T, Xiao B and Guo J: Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol. 35:5441–5447. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C, Ye H, Zhou B, Chen JJ and Chen P: Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol. 17:640–646. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, Weng WW, Tan C, Sheng WQ, Zhou XY, et al: Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 137:1128–1135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hentze MW and Preiss T: Circular RNAs: Splicing's enigma variations. EMBO J. 32:923–925. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Liu Y, Bian Z, Zhang J, Zhang R, Chen X, Huang Y, Wang Y and Zhu J: Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 Kip1 axis. Mol Cancer. 17:1512018. View Article : Google Scholar : PubMed/NCBI | |
|
Lyu D and Huang S: The emerging role and clinical implication of human exonic circular RNA. Rna Biol. 14:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J and Li H: The emerging landscape of circular RNA in life processes. Rna Biol. 14:992–999. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, Lyu D, Zheng B, Xu Y, Long Z, et al: Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 388:208–219. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Li T, Zhao Q, Xiao B and Guo J: Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim Acta. 466:167–171. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Chen H, Chen S, Mo X, Li T, Xiao B, Yu R and Guo J: Circular RNA 0000096 affects cell growth and migration in gastric cancer. Br J Cancer. 116:626–633. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B and Guo J: Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 444:132–136. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, et al: Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer. J Natl Cancer Inst. 109:2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zohny SF, Baothman OA, El-Shinawi M, Al-Malki AL, Zamzami MA and Choudhry H: The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer. Cancer Biomark. 18:413–423. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tenderenda M: A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res. 24:405–414. 2005.PubMed/NCBI | |
|
Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P and Lise M: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol. 81:167–176. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xiangming C, Natsugoe S, Takao S, Hokita S, Tanabe G, Baba M, Kuroshima K and Aikou T: The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer. 89:1214–1219. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sgambato A, Migaldi M, Leocata P, Ventura L, Criscuolo M, Di Giacomo C, Capelli G, Cittadini A and De Gaetani C: Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer. 89:2247–2257. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ichiyoshi Y, Oiwa H, Tomisaki S, Sakaguchi Y, Ohno S, Maehara Y and Sugimachi K: Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology. 44:546–553. 1997.PubMed/NCBI | |
|
Lowe SW, Cepero E and Evan G: Intrinsic tumour suppression. Nature. 432:307–315. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Long J, Menggen Q, Wuren Q, Shi Q and Pi X: MiR-219-5p inhibits the growth and metastasis of malignant melanoma by targeting BCL-2. Biomed Res Int. 2017:90325022017. View Article : Google Scholar : PubMed/NCBI | |
|
Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Compare D, Rocco A, Liguori E, D'Armiento FP, Persico G, Masone S, Coppola-Bottazzi E, Suriani R, Romano M and Nardone G: Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol. 64:677–682. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim WH: Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Komatsu S, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T, Shiozaki A, et al: Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33:271–276. 2013.PubMed/NCBI | |
|
Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M and Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 163:109–116. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, et al: Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res. 30:2453–2457. 2010.PubMed/NCBI | |
|
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K and Shirouzu K: Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Uemura T: The cadherin superfamily at the synapse: More members, more missions. Cell. 93:1095–1098. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Vleminckx K, Vakaet LJ, Mareel M, Fiers W and van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC and Yang JM: Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 8:987–993. 2002. View Article : Google Scholar : PubMed/NCBI |
